

Table S2. Significant metabolic alterations in all cohorts and subgroups.

Cohort	Subgroup	Sample size	Altered metabolite	Average Z-score	BH corrected p-value
PED-C	EP+ (n=11) vs EP- (n=20)	n=31	1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4)* 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6)* phosphatidylcholine (15:0/18:1, 17:0/16:1, 16:0/17:1)* 1-pentadecanoyl-GPC (15:0)* 1-myristoyl-GPC (14:0) Dimethylglycine 1-palmitoleoyl-GPC (16:1)* 1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6)* 1-stearyl-2-linoleoyl-GPC (O-18:0/18:2)* 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* 2-myristoyl-GPC (14:0)* 1-margaroyl-2-arachidonoyl-GPC (17:0/20:4)* 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)* 1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5)* 1-margaroyl-GPC (17:0) 1-myristoyl-2-palmitoyl-GPC (14:0/16:0) 1,2-dilinoleoyl-GPC (18:2/18:2) eicosanedioate (C20-DC)	1.1310 -0.2727 1.4787 0.5531 0.4751 -0.7356 0.7933 1.6196 -0.4542 1.0723 0.3968 0.8468 1.7798 1.9384 0.0360 1.1674 -0.5755 -0.6091	0.0007 0.0023 0.0024 0.0050 0.0050 0.0050 0.0054 0.0059 0.0068 0.0068 0.0069 0.0070 0.0123 0.0181 0.0211 0.0218 0.0370 0.0447
AD-C	EP+ (n=11) vs EP- (n=239)	n=250	C58:11 TAG C60:12 TAG C56:10 TAG C56:9 TAG C58:10 TAG C54:7 TAG C56:8 TAG C54:8 TAG C40:6 PE	-0.3627 -0.3568 -0.3521 -0.4438 -0.4803 -0.4905 -0.5078 -0.4496 -0.5396	0.0036 0.0056 0.0058 0.0118 0.0184 0.0199 0.0232 0.0215 0.0303
ELD-C	EP+ (n=26) vs EP- (n=557)	n=583	Hydrochlorothiazide	-0.2145	0.0046

Cohort	Subgroup	Sample size	Altered metabolite	Average Z-score	BH corrected p-value
ELD-C	Dyslip+: EP+ (n=9) vs EP- (n=214)	n=223	C4-OH carnitine citrulline	-0.5301 -0.5002	0.0151 0.0094
ELD-C	Dyslip-: EP+ (n=17) vs EP- (n=343)	n=360	Chenodeoxycholate Deoxycholate Cortisone chenodeoxycholate/deoxycholate	-0.4172 -0.4275 -0.2366 -0.4248	0.0007 0.0009 0.0121 0.0118
ELD-C	Prevalent (n=5) vs EP- (n=557)	n=562	C43:2 TAG Hydrochlorothiazide Cotinine Alpha-muricholate C56:2 TAG hydrocinnamic acid Thiamine C45:2 TAG C54:1 TAG C54:9 TAG Cortisone 4-Guanidinobutanoic acid C56:3 TAG C43:1 TAG C55:2 TAG anserine C24:1 Ceramide (d18:1) C42:0 TAG 4-pyridoxate C46:4 TAG	-0.5683 -0.2589 -0.2537 -0.3307 -0.5765 -0.6241 -0.1830 -0.4572 -0.5874 -0.3403 -0.2309 -0.1646 -0.6919 -0.4660 -0.6870 -0.3865 -0.7127 -0.3266 -0.2674 -0.5776	<0.001 <0.001 <0.001 <0.001 0.0081 0.0088 0.0114 0.0199 0.0359 0.0340 0.0410 0.0404 0.0381 0.0395 0.0379 0.0408 0.0472 0.0473 0.0452 0.0473
ELD-C	Incident (n=21) vs EP- (n=557)	n=578	C4-OH carnitine hydrochlorothiazide	-0.4748 -0.5372	0.0026 0.0023

Cohort	Subgroup	Sample size	Altered metabolite	Average Z-score	BH corrected p-value
AD-C	Prevalent (n=7) vs EP- (n=239)	n=246	C60:12 TAG C58:11 TAG glycoursodeoxycholate glycolithocholate C58:10 TAG C36:5 PC plasmalogen-A C56:9 TAG C54:7 TAG C56:8 TAG C40:6 PE C20:5 CE C56:10 TAG C34:0 PS C54:8 TAG C46:1 TAG C52:6 TAG C48:2 TAG C38:7 PE plasmalogen C34:2 DAG C52:7 TAG C38:6 PC succinate alanine C40:9 PC C58:9 TAG C40:6 PC C32:1 DAG C50:4 TAG	-0.4305 -0.4370 -0.4493 -0.5167 -0.5983 -0.6655 -0.5212 -0.5849 -0.6096 -0.6403 -0.8176 -0.3889 -0.8800 -0.5116 -0.4315 -0.4780 -0.4852 -0.9199 -0.4578 -0.4636 -0.8980 -0.6033 -0.6846 -1.0107 -0.5655 -0.7433 -0.4319 -0.4954	<0.001 <0.001 0.0003 0.0036 0.0048 0.0040 0.0052 0.0087 0.0146 0.0135 0.0126 0.0160 0.0181 0.0280 0.0324 0.0406 0.0409 0.0408 0.0443 0.0431 0.0463 0.0488 0.0468 0.0469 0.0512 0.0498 0.0487

EP – epilepsy, Dyslip – dyslipidemia, Prevalent – epilepsy diagnosed before sample date, Incident – epilepsy diagnosed after sample date, GPC – glycerophospholipid, DC – dicarboxylic acid, TAG – Triacylglyceride, PE – phosphatidylethanolamine, PS – phosphatidylserine, PC – phosphatidylcholine, CE – cholesteryl ester, * – the identification on metabolites marked with an asterisk is based on mass spectrometry data but no reference standards are currently available to verify the identity.